Chemomab Therapeutics (NASDAQ:CMMB) Shares Up 1.3% – Time to Buy?

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB)’s share price shot up 1.3% during trading on Friday . The stock traded as high as $1.58 and last traded at $1.55. Approximately 29,971 shares traded hands during mid-day trading, a decline of 87% from the average daily volume of 235,683 shares. The stock had previously closed at $1.53.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Chemomab Therapeutics in a research note on Friday, May 8th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $25.00.

Chemomab Therapeutics Price Performance

The firm has a market capitalization of $11.16 million, a P/E ratio of -0.70 and a beta of 0.64. The business’s 50-day moving average is $1.72 and its 200 day moving average is $1.69.

Chemomab Therapeutics (NASDAQ:CMMB) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.18). Analysts anticipate that Chemomab Therapeutics Ltd. Sponsored ADR will post -0.4 EPS for the current fiscal year.

Institutional Investors Weigh In On Chemomab Therapeutics

Several institutional investors have recently made changes to their positions in CMMB. ADAR1 Capital Management LLC acquired a new stake in Chemomab Therapeutics during the fourth quarter worth approximately $132,000. Kestra Private Wealth Services LLC acquired a new position in Chemomab Therapeutics in the 4th quarter valued at $85,000. Finally, XTX Topco Ltd acquired a new position in Chemomab Therapeutics in the 4th quarter valued at $31,000. 46.05% of the stock is currently owned by institutional investors.

About Chemomab Therapeutics

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.